GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Other Net Income (Loss)

PuraPharm (HKSE:01498) Other Net Income (Loss) : HK$0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Other Net Income (Loss)?

PuraPharm's Other Net Income (Loss) for the six months ended in Dec. 2024 was HK$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.0 Mil.


PuraPharm Other Net Income (Loss) Historical Data

The historical data trend for PuraPharm's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Other Net Income (Loss) Chart

PuraPharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PuraPharm Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PuraPharm Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of PuraPharm's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines